most common current indications for CAS is a prior ipsilateral CEA.
Restenosis after CEA is likely due to intimal hyperplasia in the first 2 years and progression of atherosclerosis or neoatherosclerosis thereafter. 3 Nevertheless, many studies, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] including one from our institution, 13, 14 have reported that patch angioplasty closure after CEA decreases the rates of restenosis as well as early occlusion. Although the chance for restenosis is significantly lowered by patch angioplasty, it still occurs. Oszkinis et al 15 reported a 9.3% cumulative incidence of carotid restenosis after CEA during an average 12-month follow-up interval. Also, Goodney et al 16 demonstrated a slight decrease in restenosis, especially in clinically significant restenosis <1 year after CEA, secondary to an increase in patching after conventional CEA and increased attention to patient safety outcomes. However, there are little data available to characterize long-term outcomes of CAS following CEA.
Although some may assume that restenosis is higher following CAS, the CREST (Carotid Revascularization Endarterectomy versus Stent Trial) investigators found rates of restenosis at 2 years were similar between CAS and CEA (6.0% vs 6.3%, respectively; p=0.58) based on a peak systolic velocity (PSV) >300 cm/s duplex criterion correlating to 70% stenosis. 17, 18 On the other hand, many respected authorities recommend CAS for restenosis after CEA, and some authors have reported the safety, feasibility, and early postoperative outcomes of CAS after CEA. [19] [20] [21] This study offers an extended follow-up comparing de novo CAS with CAS for post-CEA restenosis.
Methods

Study Design and CAS Selection Criteria
This was a retrospective review approved by the institutional review board of our tertiary care center and conducted observing the requirements established by the Health Insurance Portability and Accountability Act. The hospital billing and medical records databases were interrogated to identify all consecutive patients who underwent CAS procedures between January 1999 and December 2013. Data were retrieved on all 385 consecutive patients (mean age 68.6±9.6 years; 231 men) undergoing 435 CAS interventions over the 15-year observation period.
At our center, patients with severe carotid stenosis (70%-99% on carotid duplex) underwent extracranial carotid angiography with the possibility of revascularization. CAS was indicated for high surgical risk and stenosis ≥50% for symptomatic patients or ≥80% for asymptomatic patients, which complied with the criteria for treating asymptomatic highrisk carotid patients according to the Center for Medicare and Medicaid Services guidelines. 22, 23 All indications for revascularization were discussed in a multidisciplinary panel including vascular surgeons, vascular medicine specialists, and cardiologists. All procedures were performed using closed cell stents under embolic protection. After the procedure, duplex ultrasound surveillance was performed in an accredited [Intersocietal Commission for the Accreditation of Vascular Laboratories (ICAVL)] noninvasive vascular laboratory at 1 week, then every 3 months the first year, and every 6 months thereafter. The CAS protocol, postoperative care (including dual antiplatelet therapy with aspirin and clopidogrel), and duplex criteria for postoperative surveillance have been reported previously. 24 To analyze the long-term outcomes of CAS, patients were stratified into groups based on their history at the time of the intervention. First, CAS procedures were classified as either de novo carotid stenting (CAS-dn) or carotid stenting for post-CEA restenosis (CAS-res) subsets. They were then subdivided into either symptomatic (Sx) or asymptomatic (Asx), creating 4 groups: (1) CAS-dn Asx, (2) CAS-dn Sx, (3) CAS-res Asx, and (4) CAS-res Sx.
Endpoints and Definitions
The primary endpoints were in-stent restenosis (ISR) and target vessel reintervention (TVR). Other secondary clinical endpoints included transient ischemic attack (TIA), minor stroke, major stroke (grades III-V Rankin scale), and myocardial infarction (MI) as described previously. 24 Peripheral vascular disease (PVD) was defined as muscle discomfort in the lower limb produced reproducibly by exercise and relieved by rest within 10 minutes in patients who had no limitation for exercise. Diabetes was defined as a fasting plasma glucose level >110 mg/dL or a glycated hemoglobin >7%. Hypertension was defined as a systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg on 3 occasions during a 6-month period.
In-stent restenosis was defined as a PSV >275 cm/s using duplex ultrasound, which has been established and used by other researchers to correlate with >70% stenosis. 24, 25 TVR was defined as the need for reintervention to restore adequate flow in the target artery. Procedure success was defined as <30% residual stenosis.
Statistical Analysis
Descriptive statistics were expressed in terms of frequencies and percentages or means ± standard deviation. Categorical variables were tested with the chi-square or Fisher exact tests and continuous variables were tested using the Student t test when deemed appropriate. The threshold of statistical significance was p<0.05. The Kaplan-Meier method was used to estimate the freedom from ISR and TVR. All potential confounders were tested using Cox proportional hazards models to determine any significant predictors of ISR and TVR; results are presented as the hazard ratio (HR) and 95% confidence interval (CI). All analyses were performed using IBM SPSS Statistics for Windows (version 19.0; IBM Corporation, Somers, NY, USA).
Results
Patient Groups
The main indication for carotid angiography with possible revascularization was severe carotid stenosis (≥70%-99% on duplex) in both groups (83.6% vs 83.7%, p=0.999). The only difference between the CAS-dn and CAS-res groups was the higher incidence of congestive heart failure in the former (19.4% vs 9.5%, p=0.009). There were proportionally more women in the CAS-res group, but the difference was not significant (45.0% vs 35.2%, p=0.061). For the CAS-res group, the mean elapsed time from CEA to CAS was 72.4±63.6 months. There was no difference in the incidence of PVD between the groups (p=0.248). Symptomatic patients had more renal failure (9.2% vs 3.9%, p=0.044) but did not differ in terms of other clinical variables ( Table 1) . The time frame between index symptoms and actual stenting in the symptomatic group was 24 to 48 hours.
The majority (94.5%) of patients was treated with a single carotid stent. There were no significant differences in the percentage of patients with postintervention residual stenosis (<30%; 100% each arm) or complications between CAS-res vs CAS-dn: in-hospital stroke (1.4% vs 1.8%, respectively), MI (0.9% vs 0%), or death (0.9% vs 0%).
Mean follow-up was 62.4±45.6 months (median 53.5, range 1-180). Average clinical/TVR follow-up was longer for the CAS-res group (71.9±48.6 months) compared with 53.3±40.5 months for the CAS-dn group (p<0.001). For the ISR outcome, 64 patients had no duplex scans during the 15-year study period. The average ISR follow-up time was longer in the CAS-res group (41.8±33.3 months) compared to the CAS-dn group (27.7±30.9 months, p<0.001). Although non-significant, a higher proportion of ISR was found in the CAS-res group (15.3%) than CAS-dn group (9.6%, p=0.112), as well as more TVRs (7.9% vs. 5.9%, respectively; p=0.452). Ten patients (4 CAS-res and 6 CAS-dn) required a second reintervention.
There were significantly fewer patients presenting with symptoms in the CAS-res (45.8%) vs CAS-dn (59.7%) group (p=0.004). There were more indications for stroke and neck irradiation in the CAS-dn group [9.5 vs 4.7% (p=0.062) and 14.0 vs. 0.9% (p<0.001), respectively; Table 2 ). However, there was no difference for ISR or TVR in symptomatic compared with asymptomatic patients [ISR: 12.6% vs 12.0% (p=0.875) and TVR: 6.1% vs 7.8% (p=0.571)]. There was no difference in freedom from ISR across the 4 study groups (p=0.174; Figure 1A ). Likewise, there was no difference in the freedom from TVR across the study groups (p=0.856; Figure 1B) .
During univariate analysis, no medication-either preoperative or discharge-was found to have any significant effect on ISR or TVR (Table 3) . However, patients with TVR (vs those without) were more likely to be on a statin either preoperatively (70.0% vs 51.6%, p=0.059) or when discharged (76.7% vs. 59.5%, p=0.081). Multivariate analysis found PVD as the sole independent predictor of ISR (HR 1.92, 95% CI 1.03 to 3.62, p=0.041], while significant predictors for TVR were age at the time of the procedure (<65 years, HR 2.55, 95% CI 1.05 to 6.18, p=0.039) and PVD (HR 2.46, 95% CI 1.03 to 5.87, p=0.043).
Discussion
Although not the only etiology, extracranial carotid atherosclerosis is a common cause of ischemic stroke and amenable to surgical treatment to prevent an ischemic cerebral event. For symptomatic de novo carotid stenosis, CEA remains the standard of care in our institution. However, CAS may be the preferred treatment for selected patients under certain circumstances. One of the areas in which CAS intuitively makes the most sense is recurrent disease following CEA, but there is limited objective data related to long-term outcomes on that front. In a small series of 27 patients, 8% to 19% restenosis rates were noted after CEA and up to 25% of patients were symptomatic. 19 The Vascular Study Group of New England 26 reported that rates for the composite endpoint of stroke/death/MI were statistically similar between repeat CEA vs CAS after prior CEA in both asymptomatic (4.4% vs 3.3%, p=0.8) and symptomatic patients (6.6% vs 5.8%, p=0.9). Also, there was no significant difference in >70% restenosis between repeat CEA and post-CEA CAS groups (5.2% vs 3.0%, p=0.5). However, patients with repeat CEA had increased stroke/death/MI rates in both symptomatic (6.6% vs 2.3%, p=0.05) and asymptomatic (4.4% vs 1.7%, p=0.03) subgroups compared to primary CEA. In addition, a prior ipsilateral CEA was an independent predictor for stroke/death/MI among all patients undergoing CEA [odds ratio (OR) 2.1, 95% CI 1.3 to 3.5].
A similar review from our institution 27 with a mean follow-up of 33 months indicated that CAS is as safe as repeat CEA. However, repeat CEA had a higher incidence of transient cranial nerve injury, while CAS had a higher incidence of >50% ISR. Also, Attigah et al 20 reported similar midterm overall survival between the two groups. There is a perceived advantage of CAS in recurrent carotid stenosis, including reductions in local and neurological complications in experienced hands, which has promoted significant enthusiasm among multiple authorities for adopting CAS as a valid option for treating recurrent restenosis after ipsilateral CEA. 20, [26] [27] [28] [29] [30] In terms of symptom status, the ongoing Athero-Express study 31 indicates that the rate of restenosis is higher in patients treated for asymptomatic atherosclerotic disease compared with more vulnerable plaques. The study quantified the plaque at 2-year periods, including collagen, calcifications, lipid cores, plaque thrombosis, macrophages, smooth muscle cells, and microvessels. Interestingly, large atheroma, plaque thrombosis, macrophages, and calcifications were less frequently observed over time and reflect the current enforcement of risk factor stratification by vascular specialists.
In the current study, patients were followed prospectively with duplex scans at 1, 6, and 12 months and then every 12 months thereafter. Although it did not reach statistical significance, ISR was higher in the CAS-res group, which may warrant close follow-up. Bowser et al 32 reported findings similar to our study, as 16% of patients required reinterventions following repeat CEA. We have previously reported a trend toward a higher restenosis rate during follow-up for patients treated with CAS after ipsilateral CEA, 24 which persisted in the current study.
It seems intuitive that medications could influence ISR, but this has never held true in carotid disease or other domains. Some researchers have reported that perhaps aspirin use provides a protective effect against ISR. [33] [34] [35] The most important lesson from this finding for our group is that we should strive to achieve >95% compliance with aspirin therapy in all our carotid patients. Unexpectedly, under univariate analysis, we found that statin use preoperatively or at discharge was associated with an increased risk for ISR. However, this finding did not hold up under multivariate analysis. The opposite, a protective effect of statin use, has been widely presented by other researchers. Tadros et al 36 indicated the protective effect of statin use against embolic particles during CAS (statin: 16.4±2.1 vs no statin: 42.4±9.5, p=0.001). Also, Perler 37 in his comprehensive review highlighted pleiotropic effects of statins with 3 times the risk reduction in the rate of perioperative stroke (p<0.05) and a five fold reduction in perioperative mortality (p<0.05) among 1566 patients who underwent CEA. In that report, the advantages of using statins was confirmed in a series of >3000 CEAs performed at multiple Canadian hospitals where statin use was independently associated with a 75% reduction (OR 0.25, 95% CI 0.07 to 0.90) in the odds of death and a 45% reduction (OR 0.55, 95% CI 0.32 to 0.95) in the odds of ischemic stroke or death among patients with symptomatic carotid disease. There could be at least three possible reasons for our finding. First, it could be due to an Continuous data are presented as the means ± standard deviation; categorical data are given as the counts (percentage).
anomaly in our data and not be a true finding. It is most likely that statin use data could be serving as a marker for more severe disease, and correspondingly, these patients were more likely to develop ISR. On the other hand, our finding could be a true finding, but lacked statistical power under multivariate analysis. Predictors of restenosis were evaluated in CREST 18 ; the study identified female gender (HR 1.79, 95% CI 1.25 to 2.56), diabetes (HR 2.31, 95% CI 1.61 to 3.31), and dyslipidemia (HR 2.07, 95% CI 1.01 to 4.26) as independent predictors of restenosis at 2 years. Interestingly, smoking predicted an increased rate of restenosis after CEA (HR 2.26, 95% CI 1.34 to 3.77) but not after CAS (HR 0.77, 95% CI 0.41 to 1.42). 17 In our review, we did not find gender or dyslipidemia to be independent predictors, but only PVD, which was also an independent predictor of TVR along with age <65 years. An important recent meta-analysis 38 reported short-term outcomes of 13 studies that included 1132 patients who were treated with CAS or CEA for carotid restenosis after previous CEA. Symptomatic lesions were treated with CAS (30%) or with CEA (40%). After adjusting for all confounders, there was no difference in the endpoint between the groups (2.3% vs 2.7%; adjusted OR 0.8, 95% CI 0.4 to 1.8). Also, over a 13-month median follow-up, there was no difference in the risk of restenosis between the groups, although cranial nerve injuries were more common in CEA patients.
Another large series by New et al 39 evaluated 338 patients who underwent CAS with an average interval from CEA of 5.5±7.3 years (39% symptomatic). The authors stated that CAS can be performed safely in patients with restenosis following CEA, with results comparable to most published studies on repeat CEA.
The comparative analysis between CAS-res (n=1996) and CAS-dn (n=10,122) in the CARE (Carotid Artery Revascularization and Endarterectomy) study 40 utilized propensity score matching based on 28 characteristics to match 1756 patients in each CAS cohort. Authors reported that CAS-res patients had lower procedural adverse event rates and comparable 30-day adverse event rates compared with the CAS-dn group. In addition, other reports have detailed the importance of considering CAS as a low-risk procedure for recurrent carotid stenosis after CEA. 20, 24, 40 Cuadra et al, 41 in their series of 217 CAS procedures, showed no significant difference between 30-day stroke and stroke + mortality rates between the 2 groups. This study agreed with our report, as there was no significant difference in the composite of death, stroke, or MI at 30 days. To the best of our knowledge, this current study offers the longest follow-up outcomes for patients who had CAS after CEA (Table 4) .
Limitations
First, this was a retrospective study of existing data and, thus, carries all of the inherent bias related to selecting rather than assigning patients to treatment groups. As a consequence, patients received intervention based on intention to treat and the two groups may not be comparable. Next, some patients were lost to follow-up and did not complete the planned 6-month or annual testing. In addition, we were limited by the information that was collected and/or included in the electronic medical record. And finally, we were limited as to potential confounding variables, such as comorbidities and medications. We believe that our finding of a higher risk of ISR for discharge statin use is most likely a true finding, but likely reflected a substitute marker for more severe disease and aggressive medical treatment, rather than a negative impact from statin use. We did not randomize discharge drug treatment, and this study was not designed to test the effects of discharge statin use.
Conclusion
The current study provides the first long-term outcome analysis of carotid angioplasty after CEA versus de novo CAS. The study supports previous shorter term or small sample size trials suggesting that CAS is a safe and feasible therapeutic option in patients with recurrent stenosis following CEA. Though nonsignificant, more ISR and TVR were found in patients with a history of CEA. The study results also suggest that PVD is an independent predictor of ISR and TVR, while age at the time of the procedure is an additional predictor of TVR.
